Showing 2971-2980 of 3223 results for "".
- ProtoKinetix AAGP Dry Eye Therapy Program Launchedhttps://modernod.com/news/protokinetix-aagp-dry-eye-therapy-program-launched/2477115/ProtoKinetix announces the initiation of a program testing AAGP to develop a potential therapy to treat dry eye disease (DED). AAGP has demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations, according to a com
- Glaukos Completes Acquisition of Avedrohttps://modernod.com/news/glaukos-completes-acquisition-of-avedro/2477110/Glaukos announced that it has completed its previously announced acquisition of Avedro. In August, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction. Under the terms of the
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Drug Rhokiinsahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-drug-rhokiinsa/2477111/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension. The marketing authorization a
- Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agencyhttps://modernod.com/news/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency/2477104/Tarsius Pharma announced that the European Medicines Agency (EMA) approved the designation of orphan drug for its TRS for treatment of noninfectious uveitis and has acknowledged the clinically relevant advantage for TRS in noninfectious uveitis patients with glaucoma not eligible for corticostero
- Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technologyhttps://modernod.com/news/armenian-eyecare-project-surpasses-milestone-of-10000-patients-screened-using-artificial-intelligence-eye-screening-technology/2477088/On this World Diabetes Day, the Armenian EyeCare Project (AECP), a nonprofit organization dedicated to eliminating preventable blindness in Armenia, announced that it has surpassed the milestone of screening 10,000 patients for diabetic retinopathy (DR) throughout Armenia utilizing the state-of-a
- Solving a Medical Mystery Crucial to Future Space Travelhttps://modernod.com/news/solving-a-medical-mystery-crucial-to-future-space-travel/2477089/Astronauts often wrestle with blurry vision during spaceflight and this problem is jeopardizing longer missions to Mars, according to a report in Medscape. Half of the astronauts on the International Space Station have already expe
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- Omeros Announces Publication of Study Results on the Impact of Omidria on Opioid Use and Painhttps://modernod.com/news/omeros-announces-publication-of-study-results-on-the-impact-of-omidria-on-opioid-use-and-pain/2477067/Omeros announced that results of a prospective, controlled study showing that Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published in the peer-reviewed journal Clinical Oph
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- EyePrint Prosthetics Releases New Scleral Lens Technology: ScanFitPROhttps://modernod.com/news/eyeprint-prosthetics-releases-new-scleral-lens-technology-scanfitpro/2477058/EyePrint Prosthetics has announced the development of its new scleral lens fitting software, ScanFitPRO. This new technology simplifies every-day contact lens fitting by employing EyePrint Prosthetic’s scleral lens designer algorithm to automatically design a lens in 3-dimensional space, accordin